CD4 + T cell senescence is associated with reduced reactogenicity in severe/critical COVID-19

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

Aging is a critical risk factor for unfavorable clinical outcomes among COVID-19 patients and may affect vaccine efficacy. However, whether the senescence of T cells impact the progression to severe COVID-19 in the elderly individuals remains unclear.

Methods

By using flow cytometry, we analyzed the frequency of senescent T cells (Tsens) in the peripheral blood from 100 elderly patients hospitalized for COVID-19 and compared the difference between mild/moderate and severe/critical illness. We also assessed correlations between the percentage of Tsens and the quantity and quality of spike-specific antibodies by ELISA, neutralizing antibody test kit and Elispot assay respectively, cytokine production profile of COVID-19 reactive T cells as well as plasma soluble factors by cytometric bead array (CBA).

Results

We found a significant elevated level of CD4 + Tsens in severe/critical disease compared to mild/moderate illness and patients with a higher level of CD4 + Tsens (>19.78%) showed a decreased survival rate as compared to those with a lower level (<19.78%), especially in the breakthrough infection. The percentage of CD4 + Tsens was negatively correlated with spike-specific antibody titers, neutralization ability and COVID-19 reactive IL-2 + CD4 + T cells. Additionally, IL-2 producing T cells and plasma levels of IL-2 were positively correlated with antibody levels.

Conclusion

Our data illustrated that the percentage of CD4 + Tsens in the peripheral blood could act as an efficient biomarker for the capacity of spike-specific antibody production and the prognosis of severe COVID-19, especially in the breakthrough infection. Therefore, restoration of the immune response of CD4 + Tsens is one of the key factors to prevent severe illness and improve vaccine efficacy in older adults.

Article activity feed